Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers

Open access

Published version of a preprint

Abstract

Loss-of-function mutations in p16INK4A (CDKN2A) occur in approximately 80% of sporadic pancreatic ductal adenocarcinoma (PDAC), contributing to its early progression. Although this loss activates the cell-cycle–dependent kinases CDK4/6, which have been considered as drug targets for many years, p16INK4A-deficient PDAC cells are inherently resistant to CDK4/6 inhibitors. This study searched for targeted therapies that might synergize with CDK4/6 inhibition in this setting. We report that the IGF1R/IR inhibitor BMS-754807 cooperated with the CDK4/6 inhibitor PD-0332991 to strongly block proliferation of p16INK4A-deficient PDAC cells in vitro and in vivo. Sensitivity to this drug combination correlated with reduced activity of the master cell growth regulator mTORC1. Accordingly, replacing the IGF1R/IR inhibitor with the rapalog inhibitor temsirolimus broadened the sensitivity of PDAC cells to CDK4/6 inhibition. Our results establish targeted therapy combinations with robust cytostatic activity in p16INK4A-deficient PDAC cells and possible implications for improving treatment of a broad spectrum of human cancers characterized by p16INK4A loss. Cancer Res; 74(14); 3947–58. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-2923

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 119

Metadata

Authors
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J.
Affiliations
Harvard University (US)
Venue
Cancer Research
Published
2014-07-14
Volume
74
Issue
14
Pages
3947-3958
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2134964281
Cited by
119
References
39
Citations by year
2026: 8 · 2025: 2 · 2024: 5 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 12 · 2019: 11 · 2018: 19 · 2017: 11 · 2016: 8 · 2015: 13 · 2014: 3
FWCI
5.62
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Massachusetts General Hospital
  • National Cancer Institute (CA165856, F32CA165856, R01CA155202, R01CA163698)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
pancreatic ductal adenocarcinoma, CDK4/6 inhibitors, BMS-754807, palbociclib, temsirolimus, mTORC1, drug synergy, CDKN2A loss, combination therapy, cell proliferation
MeSH terms
Tuberous Sclerosis Complex 2 Protein, Animals, Cell Survival, Disease Models, Animal, Drug Synergism, Female, Humans, Pancreatic Neoplasms, Phosphorylation, Retinoblastoma Protein, Cellular Senescence, Gene Deletion, Receptor, IGF Type 1, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p16, Xenograft Model Antitumor Assays, Tumor Suppressor Proteins, Ribosomal Protein S6 Kinases, 70-kDa, Cell Line, Tumor, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, TOR Serine-Threonine Kinases, G1 Phase Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-2923
The paper
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014). CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-2923

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.